Treatment for chemotherapy-induced peripheral neuropathy using traditional Chinese medicine hot packages

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of traditional Chinese medicine hot packages in treating chemotherapy-induced peripheral neuropathy (CIPN) in patients undergoing chemotherapy with platinum and taxane drugs. A total of 90 participants will be randomly assigned to either a control group, receiving standard chemotherapy care, or an intervention group, which will also receive hot compress treatments at acupuncture points. The study aims to assess the degree of nerve damage and patient-reported outcomes after chemotherapy cycles. The approach combines modern chemotherapy with traditional Chinese medicine to potentially improve patient quality of life.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult and kinetic patients expected survive with tumor for more than 1 year. Those who use platinum in combination with paclitaxel for chemotherapy for the first time; Voluntarily agree to participate and sign a consent form

Exclusion Criteria:

* Those who are allergic to platinum, paclitaxel or Chinese herbal medicine ingredients; Patients with diabetes mellitus, Raynaud's syndrome, central or peripheral nerve disease symptoms; Those who cannot judge their own symptoms; Pregnant / lactating women; Patients with advanced rheumatoid arthritis, severe joint deformity or incapacitation; Those with other immune system diseases； Patients who have not completed the chemotherapy regimen; Patients who were not treated with hot acupuncture points as prescribed (missed dosing ≥ 3 times per week); Incomplete collection of clinical data; Subjects who voluntarily request to withdraw from this treatment, or are unwilling to continue treatment.

Where it's running

• the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine
  Yiwu, Zhejiang, China Recruiting

Study contacts

• Principal investigator: Lin Dong, Bachelor — The Fourth Affiliated Hospital of Zhejiang University School of Medicine
• Study coordinator: Lin Dong, Bachelor
• Email: dong13634187314@163.com
• Phone: 86+13634187314

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Gait Changes in Breast Cancer Patients Receiving Chemotherapy

  This study tests how chemotherapy affects walking and balance in women with breast cancer.

  Recruiting Cairo University · Cairo, Cairo Governorate · NCT07894133

• Targeted Induction Therapy for Stage III Unresectable EGFR Mutant NSCLC

  This trial tests a targeted induction approach using fumetinib with platinum-based chemotherapy and concurrent radiochemotherapy in adults with unresectable stage III EGFR-mutant NSCLC to see if this combo can improve outcomes before possible surgery.

  Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT07742332

• VR-guided mindfulness for anxiety, sleep, comfort, and fatigue in women with breast cancer undergoing chemotherapy

  This study tests whether a virtual reality–based mindfulness program can help women with breast cancer feel less anxious, sleep better, feel more comfortable, and have less fatigue during chemotherapy.

  Recruiting Hacettepe University · Ankara, Ankara · NCT07731477

• Using plasma ctDNA methylation to guide adjuvant chemotherapy for high-risk T3N0 colorectal cancer

  This will test whether a blood ctDNA methylation test can help choose stronger chemotherapy after surgery for people with high-risk T3N0 (stage II) colorectal cancer who are ctDNA-positive one month after surgery.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07562711

• Plasma ctDNA methylation-guided adjuvant chemotherapy for people with T4N0 and low‑risk stage III colorectal cancer.

  This trial will test whether using a blood test (plasma ctDNA methylation) to guide 3 vs 6 months of adjuvant chemotherapy or to switch regimens helps people with T4N0 or low‑risk stage III colorectal cancer after surgery.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07562503

• Plasma ctDNA methylation–guided adjuvant chemotherapy for high-risk stage III colorectal cancer

  This trial will test whether adding bevacizumab to standard FOLFOX or CAPOX chemotherapy based on plasma ctDNA results helps adults with high-risk stage III colorectal cancer (T4N+ or T1-3N2).

  Recruiting Phase 2 Fudan University · Shanghai · NCT07562490

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.